Related Experiment Video
Updated: Aug 18, 2026

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli
Published on: June 27, 2015
Differential effects of T- and L-type calcium antagonists on glomerular dynamics in spontaneously hypertensive rats
Y Nakamura1, H Ono, E D Frohlich
1Hypertension Research Laboratories, Alton Ochsner Medical Foundation, New Orleans, LA, USA.
Insights
Both T-type (mibefradil) and L-type (amlodipine) calcium channel blockers effectively treated hypertensive nephrosclerosis in rats. Mibefradil showed a greater reduction in afferent arteriolar resistance while maintaining glomerular filtration.
Area of Science:
- Nephrology
- Pharmacology
- Cardiovascular Physiology
Background:
- Hypertensive nephrosclerosis is a significant complication of hypertension.
- N(G)-nitro-L-arginine methyl ester (L-NAME) is used to induce nephrosclerosis in spontaneously hypertensive rats (SHR).
- T-type and L-type calcium channel blockers have distinct physiological roles.
Purpose of the Study:
- To compare the effects of T-type (mibefradil) and L-type (amlodipine) calcium antagonists on hemodynamics and nephrosclerosis in L-NAME-treated SHR.
- To investigate the impact of these antagonists on systemic, renal, and glomerular parameters.
Main Methods:
- Seven groups of male SHR were studied, including control, drug-treated, and L-NAME-induced nephrosclerosis groups.
- Animals received L-NAME in drinking water, with or without mibefradil or amlodipine, in various treatment and withdrawal regimens.
- Hemodynamic parameters, renal pathology, urinary protein excretion, and organ masses were assessed.
Main Results:
- Both mibefradil and amlodipine reduced mean arterial pressure and total peripheral resistance.
- Glomerular arteriolar resistances, ultrafiltration coefficient, and urinary protein excretion were significantly improved by both drugs.
- Mibefradil demonstrated a more pronounced reduction in afferent arteriolar resistance compared to amlodipine, with preserved single-nephron glomerular filtration ratio (SNGFR).
Conclusions:
- T-type and L-type calcium antagonists effectively prevented and reversed L-NAME-induced hypertensive nephrosclerosis in SHR.
- Mibefradil, a T-type antagonist, appeared more effective than amlodipine, an L-type antagonist, in improving specific hemodynamic and renal parameters.
Abstract:
To determine whether there is a difference in the effects of T- and L-type calcium antagonists on systemic, renal, and glomerular hemodynamics, the pathological changes of N(G)-nitro-L-arginine methyl ester (L-NAME)-exacerbated nephrosclerosis and clinical alterations were investigated in spontaneously hypertensive rats (SHR). Seven groups of 17-week-old male SHRs were studied: Group 1, control; Group 2, mibefradil, 50 mg. kg(-1). d(-1); Group 3, L-NAME in drinking water, 50 mg/L; Group 4, L-NAME (50 mg/L) plus mibefradil (50 mg. kg(-1). d(-1)); Group 5, L-NAME (50 mg/L) plus amlodipine (10 mg. kg(-1). d(-1)); Group 6 and 7, L-NAME (50 mg/L) for 3 weeks followed by mibefradil (50 mg. kg(-1). d(-1)) or amlodipine (10 mg. kg(-1). d(-1)), respectively, for the subsequent 3 weeks. Both the T- and L-channel calcium antagonists similarly reduced mean arterial pressure and total peripheral resistance index. These changes were associated with significant decreases in afferent and efferent glomerular arteriolar resistances and the ultrafiltration coefficient (P<0.01). Furthermore, the histopathological glomerular and arterial injury scores and urinary protein excretion were also significantly improved (P<0.01), and left ventricular and aortic masses were significantly diminished in all treated groups. Both drugs, mibefradil and amlodipine, had effects of increasing the single-nephron glomerular filtration ratio (SNGFR), and single-nephron plasma flow (SNPF), and of reducing glomerular afferent arteriolar resistance and urinary protein excretion. Thus, the T-type (mibefradil) and L-type (amlodipine) calcium antagonists each prevented and reversed the pathophysiological alterations of L-NAME-exacerbated hypertensive nephrosclerosis in SHR. The T-type calcium antagonist (mibefradil) seemed to have been more effective than the L-type amlodipine antagonist and it produced a greater reduction in afferent arteriolar resistance while preserving SNGFR.
Related Concept Videos
Antihypertensive Drugs: Action of Diuretics
Antihypertensive Drugs: Potassium-Sparing Diuretics
Antihypertensive Drugs: Action of β1 Blockers
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Glomerular Filtration Rate and its Regulation
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...

